EricSamuelNadlerMD

Oncology • Dallas, TX

Physician

Join to view full profile

Dr. Nadler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nadler's full profile

Already have an account?

Office
3410 Worth St
Dallas, TX 75246
Phone+1 214-370-1000

Fax+1 214-370-1026

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2003 - 2005
Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2003
Harvard Medical SchoolClass of 2000

Certifications & Licensure

TX State Medical License 2005 - 2025
MA State Medical License 2002 - 2007
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers Start of enrollment: 2010 Jun 01
Completed
Phase 3
Optimal Tube Feeding Method in Head and Neck Cancer Patients Start of enrollment: 2015 Feb 01
Terminated
Not Applicable
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Start of enrollment: 2015 Oct 05
Terminated
Phase 1, Phase 2

Publications & Presentations

PubMed

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.
Xiuning Le, Eric Nadler, Daniel B Costa, John Victor Heymach
Targeted Oncology. 2024-01-01
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.
Xiuning Le, Eric Nadler, Daniel B Costa, John Victor Heymach
Targeted Oncology. 2023-11-01
2 citations
EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.
Xiuning Le, Eric Nadler, Daniel B Costa, John Victor Heymach
Targeted Oncology. 2023-11-01

Press Mentions

US Oncology Research, the US Oncology Network and Ontada Announce Clinical Data Showcased in Plenary and Oral Sessions at ASCO Annual MeetingJune 3rd, 2021
OncLive® Presents State of the Science Summit™ on Non-Small Cell Lung CancerApril 16th, 2019